October 14, 2025/
This document is a Direct Healthcare Professional Communication (DHPC) issued in August 2025 by a Marketing Authorization Holder (MAH) in agreement with the Egyptian Drug Authority. Its primary purpose...
ALVigiLance is a dedicated pharmacovigilance platform designed to support the healthcare team in ensuring safer medication use. Our mission is simple yet vital: to provide trusted insights, practical tools, and up-to-date resources that empower healthcare professionals to identify, prevent, and manage adverse drug reactions (ADRs).
Simplified, practical guides on drug safety and monitoring.
Real-world examples to strengthen your clinical decision-making.
Summaries of global drug warnings and regulatory actions.
Strategies for adverse event reporting, risk management, and patient counseling.
To create a proactive community of healthcare providers who champion medication safety and improve patient outcomes through shared knowledge and vigilance.
Medication safety is everyone’s responsibility. Explore, learn, and engage with ALVigiLance — because together, we can reduce risks and save lives.
This document is a Direct Healthcare Professional Communication (DHPC) issued in August 2025 by a Marketing Authorization Holder (MAH) in agreement with the Egyptian Drug Authority. Its primary purpose...
This document is a European Medicines Agency (EMA) publication, specifically from the Pharmacovigilance Risk Assessment Committee (PRAC). It details new safety information for several medicines, based on recommendations adopted in September...
This document is an official guideline from the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA). It provides a comprehensive framework for the...
